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Abstract
Background: Published data suggest a link between obesity and 
adverse outcomes in Crohn’s disease (CD). We aimed to test the 
hypothesis that obese CD patients would be more likely than non-
obese CD patients to have poor surgical outcome when undergoing 
surgery for a complication of CD.
Methods: We designed a retrospective cohort study to test our 
hypothesis. The population comprised of adult CD patients who 
underwent CD related surgery at a tertiary referral center. The ex-
posed and unexposed cohorts were represented by patients who 
were obese vs. non-obese at the pre-op visit respectively. Outcome 
was represented by successful vs. unsuccessful surgical outcome as 
deemed by the treating clinician.
Results: Ninety CD patients were eligible for inclusion into this 
cohort study of which 36 were obese (exposed cohort) and 54 were 
non-obese (unexposed cohort). Among obese CD patients, 64% had 
an unsuccessful surgical outcome vs. 41% with unsuccessful surgi-
cal outcome among the non-obese. Based on unadjusted bivariate 
analysis, potential confounders identified included age and type of 
surgery. Gender distribution, disease duration, ethnicity, tobacco 
use, steroid use, traditional and biological immune modulator use 
and clinical disease activity were similar between the two groups. 
Logistic regression adjusted for age and type of surgery revealed 
that obese CD patients were approximately 2.5 times more likely to 
have a poor surgical outcome than patients with CD who were not 
obese (P = 0.05 OR 2.53 95% CI 0.99 - 6.52). BMI as a continu-
ous variable (adjusted for age and type of surgery) appeared to be 
associated with poor surgical outcome (P = 0.06 OR 1.07 95% CI 
0.99 - 1.15).
Conclusions: Obesity may be associated with poor surgical out-
come in CD patients.
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Introduction
Crohn’s Disease (CD) is a chronic inflammatory condition, 
primarily of the gastrointestinal system that affects 750,000 
people in the US. It is characterized by transmural inflam-
mation and can involve any part of the intestinal tract [1, 2]. 
Its presentation is heterogeneous in that its clinical course 
is variably characterized by intestinal inflammation, stric-
turing of segments of the bowel causing obstruction and/
or occurrence of penetrating mucosal complications lead-
ing to intestinal perforation and formation of fistulas and/
or abscesses [3-5]. While medical management is the cor-
nerstone of therapy in almost all forms of CD, surgery is an 
inevitable treatment modality as up to 80% of CD patients 
undergo operative intervention during the course of their 
disease [3-5].
Adipose tissue is an active endocrine organ that is 
made up of elements of connective tissue as well as of cells 
represented by pre-adipocytes and adipocytes that may be 
prominent mediators of inflammation in the human body 
[6-9].Abnormally increased stores of adipose tissue in the 
body represent obesity which is measured as increased body 
weight to height ratio, also referred to as the body mass in-
dex (BMI). Standard weight is defined as BMI of 18.5 - 24.9 
kg/m2. BMI of 25.0 - 29.9 kg/m2 has traditionally represent-
ed overweight or pre-obesity. Obesity is defined as BMI of 
greater than 30 kg/m2 [6].
The importance of the need to study the association be-
tween the obese state and CD outcomes emanates from the 
observation that there is credible molecular evidence for a 
link between increased mesenteric adipose stores and intes-
tinal inflammation in CD [8, 9]. Moreover, in the past few 
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decades, obesity has undergone a marked increase in preva-
lence within the US and across the globe, and this increased 
trend of obesity is also reflected in patients with CD [10-12].
Whether the molecular association between increased 
mesenteric adipose tissue and intestinal inflammation in CD 
truly translates into a relationship between the two entities 
in clinical practice is either not well known yet or at best, 
research on it is equivocal. There has been some clinical re-
search evaluating an association between increased adipose 
tissue represented clinically by the obese state and several 
outcome parameters in CD such as clinical and mucosal dis-
ease activity as well as surgical outcomes, but further work 
needs to be done before these research questions can be ad-
equately answered [13-15].
The objective of this retrospective cohort study was to 
offer a unique perspective by systematically evaluating the 




   
Study design
This was a retrospective cohort study.
Patients
Men and women 19 years and older with CD who under-
went surgery for a complication related to CD at University 
of Alabama at Birmingham Hospital (UAB) between 2000 
and 2009 were retrospectively identified using a health sys-
tem billing search engine. In order to assure higher sensitiv-
ity, surgical log books were reviewed to identify additional 
patients.
Patients screened based on search criteria had to meet 
further inclusion and exclusion criteria. Eligible patients had 
to have established endoscopic or histological diagnosis of 
CD in addition to having surgery for a well-categorized CD 
related complication between 2000 and 2009. Data on pre-
operative BMI, demographics and post-surgical outcome in 
the patients had to be available for them to be included into 
the study. Patients were excluded if they had a BMI of less 
than 18.5 kg/m2, if they had any current history of cancer, 
were receiving chemotherapy or had missing data.
Data collection
Information obtained from review of patient charts included: 
1), demographic data (age, ethnicity, gender, and the body 
mass index); 2), clinical variables (age, smoking history, du-
ration of disease and clinical disease activity at the time of 
surgery); 3), medication history (use of steroids, traditional 
immune modulators and biological agents); 4), type of sur-
gery and 5), surgical outcome.
Data were collected from medical records onto a stan-
dard data collection form and then entered into a database. 
All recorded data were reviewed twice to ensure accuracy.
Definitions of variables
Body mass index
Obesity was measured using body mass index (BMI). BMI 
was calculated by dividing a person’s weight in kg by height 
in meters squared. Based on the BMI, patients were divided 
into two groups. Obese patients were those with a BMI of 
greater than 30 kg/m2. The rest had a BMI between 18.5 - 
29.9 kg/m2 and they were classified as non-obese. Pre-op 
height and weight were used to calculate BMI. Self- reported 
height and weight were not used to avoid recall bias.
 
Type of surgery
Surgery was categorized into one of three types according to 
invasiveness of each kind of intervention. The first category 
comprised of Seton placement (with or without a preceding 
fistulotomy), or incision and drainage for an associated peri-
anal abscess. The second type of surgery was classified as an 
advancement flap, whether it was mucosal or submucosal, 
and with or without an associated circular or a gracilis flap. 
Internal strictureplasty, internal abscess drainage and inter-
nal balloon dilations were also considered under the second 
type of surgery. The third category comprised of resective 
surgeries and included ileocecectomy, ileocolonic resection, 
colectomy and proctocolectomy. Fecal diversion procedures 
(ileostomy/colostomy) and abdominal perineal resections 
were also classified under the third type of surgery. Patients 
who underwent two categories of procedures were classified 
under the more invasive category.
Clinical disease activity
Crohn’s disease clinical activity was documented for each 
patient in accordance with American College of Gastroen-
terology practice guidelines. Patients were divided into two 
categories, those in remission or mild to moderate disease, 
and those with moderate to severe disease [4].
Medication history
History of corticosteroid use was defined as more than one 
week of conventional oral or parenteral steroids, or more 
than a month of rectal or topical steroids or more than 3 
months of oral budesonide within the past one year. Any his-
tory of oral, parenteral, rectal, topical steroids including use 
of oral budesonide within the one month prior to surgery was 
considered recent steroid use. Immune modulator use was 
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considered positive if a patient was on azathioprine (AZA), 
6-mercaptopurine (6-MP), methotrexate (MTX) or any bio-
logical agent prior to or at the time of surgery and was on the 
particular agent at the first post-op follow-up appointment.
Tobacco use
Smokers were defined as those who were smoking at time 
of surgery.
Defining outcome
Outcome of interest was unsuccessful surgical outcome at or 
before the one month post-op visit as defined by the treating 
or managing clinician. Specifically, unsuccessful or poor sur-
gical outcome was defined as any post-op complication elic-
ited during the post-op recovery period, or during the first 
post-op scheduled or unscheduled visit that required a non-
standard intervention. Minor complications were character-
ized by post-op wound infections, delayed wound healing 
or prolonged recovery. Major complications were defined 
as anastomotic leak, wound dehiscence, development of an 
intra-abdominal abscess or death. Any patient who did not 
develop any of these complications was considered to have 
had a successful surgical outcome.
Statistical analysis
Descriptive analysis
Descriptive data on demographic and clinical information 
including data on exposure and outcome variables were col-
lected for the entire cohort.
Primary bivariate analysis
Bivariate analysis comparing exposure of interest with its 
co-variates and with the outcome of interest was completed 
in order to select the co-variates to be placed in the adjusted 
regression model.
Multivariable analysis
Multivariable Logistic Regression Analysis was used to cal-
Table 1. Comparison of Obese and Non-obese Patients (Also Appears Within Text) 
*P-value < 0.05; ^P-value < 0.10.
Obese N = 36 (%) Non-obese N = 54 (%) P-value
BMI at surgery- median (range) 32.3 (30.1 - 72.4) 23.3 (18.5-28.5) < 0.0001*
Age at surgery -median (range) 45 (19 - 88) 34 (19 - 75) 0.001*
Disease duration-median (range) 8 (1 - 41) 9 (1 - 36) 0.644
Type of surgery 0.079^
Fistulotomy, Seton Placment 5 (14%) 19 (35%) 0.025*
Flap, Strictureplasty, Dilation 6 (17%) 6 (11%) 0.448
Resection, Diversion 25 (69%) 29 (53%) 0.135
Gender (male) 9 (25%) 21 (39%) 0.171
Ethnicity 0.146
Caucasian 23 (64%) 41 (76%) 0.217
African American 9 (25%) 12 (22%) 0.76
Tobacco Use 9 (25%) 13 (24%) 0.92
Moderate to Severe Disease 17 (47%) 19 (35%) 0.254
Steroid use 10 (28%) 19 (35%) 0.461
Immune modulator use 28 (78%) 48 (89%) 0.154
Azathioprine/6-MP 13 (36%) 21 (39%) 0.79
TNF blocker 17 (47%) 25 (46%) 0.931
Methotrexate 1 (3%) 8 (15%) 0.08^
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culate the adjusted odds ratio for the odds of unsuccessful 
surgical outcome vs. successful surgical outcome based on 
the exposure of interest, obesity.
Statistical analysis software
Statistical software (SAS, version 9.2; SAS Institute, Inc., 
Cary, NC) was used to perform all statistical analyses. Sta-
tistical tests were two-sided with a 5% significance level 
(namely, α = 0.05).
Study approval
This study was approved by University of Alabama’s Institu-




A total of 90 patients were eligible for inclusion into this 
retrospective cohort study. Comparison of demographic and 
clinical characteristics among the 36 exposed (obese) vs. 54 
unexposed (non-obese) patients appears in Table 1. In the 
entire cohort, 45 (50%) CD patients had poor surgical out-
come based on review by treating clinician at or before the 
one month post-op visit with 64% of them being obese vs. 
41% who were non-obese.
Based on bivariate analysis looking at clinically relevant 
co-variates, potential confounders for the association be-
tween obesity and surgical outcome identified included age 
and type of surgery (P < 0.1). Gender distribution, disease 
duration, ethnicity, tobacco use, steroid use, traditional and 
biological immune modulator use and clinical disease activ-
ity were similar between the exposed (obese) and unexposed 
(non-obese) cohort and therefore were not included into the 
adjusted model (Table 1). Unadjusted logistic regression 
analysis examining the association between obesity and sur-
gical outcome in CD demonstrated a statistical significant 
relationship (P = 0.03 OR 2.57 95% CI 1.08 - 6.14). Unad-
justed logistic regression analysis that assessed the associa-
tion between BMI as a continuous variable and surgical out-
come in CD also demonstrated results that displayed a trend 
towards significance (P = 0.07 OR 1.07 95% CI 0.99 - 1.15).
Multivariable stepwise logistic regression analysis ad-
justed for age and type of surgery revealed that obese CD 
patients were approximately 2.5 times more likely to have 
a poor surgical outcome than patients with CD who were 
not obese (P = 0.05 OR 2.53 95% CI 0.99 - 6.52) (Figure 
1). BMI as a continuous variable (adjusted for age and type 
of surgery) also predisposed CD patients to a poor surgical 
outcome (P = 0.06 OR 1.07 95% CI 0.99 - 1.15), with every 
unit increase in BMI associated with a 7% higher probability 
of having an unsuccessful surgical outcome.
Discussion
  
The most significant finding observed in this retrospective 
cohort study was that obese CD patients appeared to be more 
likely to have a poor surgical outcome when compared to 
CD patients who were not obese. It was also suggested as 
a result of marginal statistical significance that an increase 
in BMI itself may also predict a poor surgical outcome in 
patients with CD.
Review of past literature reveals that there is a paucity of 
knowledge on the influence of increased BMI on the clinical 
Figure 1. Comparison of outcome in obese vs. non-obese patients (also appears within text).
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presentation and course of CD patients. A 2002 French study 
by Blain and colleagues compared the clinical course of CD 
patients who were obese with those CD patients who were 
not obese [13]. They defined obese CD patients as those who 
had a BMI of greater than 25 kg/m2 at the time of disease 
onset and more than 30 kg/m2 at any time during the course 
of their disease thereafter. They observed that obese CD pa-
tients had a higher rate of disease flares and hospitalizations. 
But they did not detect any difference between obese and 
non-obese CD patients based on long-term outcome which 
included outcome after resective surgery in those patients 
who underwent surgery [13]. Trend of hospitalizations or 
flares were not looked at in our study. We did detect a non-
significant increased rate of clinical disease activity in obese 
patients (47%) compared to patients who were not obese 
(35%) (P = 0.254).
A 2006 US study by Hass et al also evaluated the role 
of BMI in predicting the clinical course of CD patients [14]. 
They compared overweight or obese CD patients, namely 
those who had a BMI of greater than 25 kg/m2 to CD pa-
tients who had a normal or a low BMI of less than 25 kg/m2. 
Within the group of patients with BMI < 25 kg/m2, the subset 
representing patients who had a BMI of less than 18.5 kg/
m2 were also included. In their study, the degree of therapy 
escalation required did not differ in the two CD groups as op-
posed to the study by Blain and colleagues in which they had 
observed a greater likelihood of flares and hospitalization in 
CD patients who were obese. Of note, Blain et al had com-
pared obese patients to those who were non-obese whereas 
Hass and colleagues had combined overweight and obese 
patients into one group. Interestingly, Hass et al did find that 
when compared to the subset of patients who had a BMI of 
less than 18.5 kg/m2, overweight/obese patients (BMI of 
greater than 25 kg/m2) had a much shorter time to first sur-
gical intervention [14]. Underweight CD patients were not 
included in the studied patient population because during the 
initial pre-screening, there were only three patients who had 
a BMI of less than 18.5 kg/m2 and thus they were excluded.
On comparing the sub-groups of standard weight (BMI 
of 18.5 - 24.9 kg/m2) and overweight (BMI of 25 - 29.9 kg/
m2) patients within our non-obese population, it was ob-
served that the difference in surgical outcome between them 
was not significantly different. The slightly improved, albeit 
non-significant surgical outcome in the overweight popula-
tion compared to those who were of standard weight may be 
because the current criteria for dividing individuals between 
normal weight and overweight are perhaps too stringent. The 
most ill CD patients characteristically suffer from under-
nourishment and loss of weight. When CD patients are in 
remission or have only mild symptoms, they gain weight. It 
is entirely possible that during their healthiest period, they 
cross the barrier between standard weight and overweight. 
Moreover, BMI is not able to reliably distinguish between 
muscle weight and weight from fat. It is therefore also entire-
ly possible that many overweight CD patients in our patient 
population represented the healthiest patients in our cohort. 
Lastly, BMI may not be a reliable surrogate for mesenteric 
fat content.
Retrospective design, lack of a group representing un-
derweight CD patients and a relatively small sample size 
were among several important limitations of our study. Also, 
the lack of homogeneity in regard to type of surgery was 
another limitation that was partially accounted for by in-
clusion of this clinically important factor into the adjusted 
multivariable regression model. Confounding by indication 
was another concern in this study. For example, more severe 
cases may have been more likely to be on biological immune 
modulators. At the same time, they may also have had bet-
ter disease control at the time of surgery. This element was 
probably not a major confounder in our study as the rates 
of traditional and biological immune modulators were simi-
lar in the obese and non-obese patients. Moreover, data on 
previous surgeries and number of previous surgeries were 
also not included in our analysis; this information may have 
impacted outcomes in individual CD patients.
In order to make further progress on this topic, there is 
a need for larger studies, preferably prospective that include 
a larger spectrum of BMI groups as well as a larger patient 
population in each respective group. Additionally, larger 
studies will allow inclusion of more co-variates into adjusted 
models to better account for potential confounding and will 
have additional statistical power to detect important differ-
ences between groups.
Finally, in order to better identify the threshold of in-
creased post-operative risk in regard to BMI, future studies 
should also consider comparing the clinical course and out-
come of obese CD patients on one side to the clinical course 
and outcome of overweight and normal weight CD patients 
combined as one group on the other.
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